Published in Trans R Soc Trop Med Hyg on July 19, 2007
Targeted Chemo-elimination (TCE) of Malaria (TME) | NCT01872702
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother (2012) 3.12
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One (2009) 2.43
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther (2012) 1.87
Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One (2009) 1.73
Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother (2011) 1.67
The global pipeline of new medicines for the control and elimination of malaria. Malar J (2012) 1.57
An open-label, randomised study of dihydroartemisinin-piperaquine versus artesunate-mefloquine for falciparum malaria in Asia. PLoS One (2010) 1.48
Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg (2011) 1.44
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev (2014) 1.38
Drug-Resistant Malaria: The Era of ACT. Curr Infect Dis Rep (2010) 1.33
Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother (2012) 1.30
Malaria-infected mice are cured by a single oral dose of new dimeric trioxane sulfones which are also selectively and powerfully cytotoxic to cancer cells. J Med Chem (2009) 1.23
Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J (2009) 1.12
A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One (2010) 1.11
Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 1.10
Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers. Antimicrob Agents Chemother (2013) 1.08
In vitro selection of Plasmodium falciparum drug-resistant parasite lines. J Antimicrob Chemother (2009) 1.07
Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis (2013) 1.07
Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother (2011) 1.06
Malaria-infected mice live until at least day 30 after a new monomeric trioxane combined with mefloquine are administered together in a single low oral dose. J Med Chem (2009) 1.04
Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda. Malar J (2008) 1.02
Monitoring Plasmodium falciparum chloroquine resistance in Yunnan Province, China, 1981-2006. Acta Trop (2008) 0.99
New perspectives on chinese herbal medicine (zhong-yao) research and development. Evid Based Complement Alternat Med (2011) 0.97
MMV in partnership: the Eurartesim® experience. Malar J (2013) 0.97
A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice. Bioorg Med Chem Lett (2010) 0.95
In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica (2012) 0.94
Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar J (2012) 0.94
Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob Agents Chemother (2007) 0.90
Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats. Malar J (2009) 0.86
Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine. J Med Chem (2011) 0.85
Antimalarial Preclinical Drug Development: A Single Oral Dose of A 5-Carbon-linked Trioxane Dimer Plus Mefloquine Cures Malaria-Infected Mice. Drug Dev Res (2009) 0.82
Piperaquine pharmacodynamics and parasite viability in a murine malaria model. Antimicrob Agents Chemother (2009) 0.79
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. PLoS One (2013) 0.79
An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat. Malar J (2012) 0.78
Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis (2016) 0.75
Malaria-Infected Mice Are Cured by a Single Low Dose of a New Silylamide Trioxane Plus Mefloquine. Pharmaceuticals (Basel) (2009) 0.75
Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. Br J Clin Pharmacol (2017) 0.75
Averting a malaria disaster. Lancet (1999) 9.40
Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis (1989) 8.24
Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol (2000) 7.77
Effects of artemisinin derivatives on malaria transmissibility. Lancet (1996) 7.42
Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol (1985) 7.14
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Neurological manifestations of dengue infection. Lancet (2000) 5.69
Maternal antibodies block malaria. Nature (1998) 5.67
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
Qinghaosu. Lancet (1993) 5.25
Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet (1993) 5.11
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol (1993) 4.98
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med (1996) 4.64
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother (1999) 4.64
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg (1999) 4.60
Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis (1997) 4.53
The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg (1997) 4.48
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health (2004) 4.35
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis (1994) 4.17
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 3.72
A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol (1999) 3.72
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet (2002) 3.65
Effects of Plasmodium vivax malaria in pregnancy. Lancet (1999) 3.62
Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol (1989) 3.57
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 3.46
Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg (1998) 3.39
Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg (2001) 3.32
Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 3.32
The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol (1994) 3.23
The sick placenta-the role of malaria. Placenta (2004) 3.18
Neurological sequelae of cerebral malaria in children. Lancet (1990) 3.11
Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg (1992) 3.10
Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med (1983) 3.07
Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet (1985) 3.03
Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol (1998) 3.02
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (1999) 2.98
Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg (1999) 2.94
Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg (1993) 2.90
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis (2008) 2.77
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun (1997) 2.72
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med (1982) 2.71
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology (2002) 2.67
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis (2011) 2.65
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (1998) 2.61
Relapse in melioidosis: incidence and risk factors. J Infect Dis (1993) 2.61
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis (1996) 2.59
Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg (1998) 2.54
Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Trans R Soc Trop Med Hyg (1996) 2.54
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Paracheck-Pf: a new, inexpensive and reliable rapid test for P. falciparum malaria. Trop Med Int Health (2001) 2.54
Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J Clin Microbiol (2001) 2.53
High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet (1987) 2.52
The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis (1999) 2.49
Comparison of multilocus sequence typing and pulsed-field gel electrophoresis as tools for typing Staphylococcus aureus isolates in a microepidemiological setting. J Clin Microbiol (2002) 2.45
The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother (1989) 2.44
Microsatellite variation, repeat array length, and population history of Plasmodium vivax. Mol Biol Evol (2006) 2.43
The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med (2000) 2.42
The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet (1996) 2.41
Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet (1998) 2.41
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother (2001) 2.40
The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol (1990) 2.39
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis (2000) 2.35
Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma. Trans R Soc Trop Med Hyg (1997) 2.33
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet (1996) 2.33
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother (2008) 2.27
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg (1996) 2.24
Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis (1994) 2.23
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother (2008) 2.23
Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg (1999) 2.23